Displaying 1 - 20 of 75 tests
Naphthyl Acetate Esterase (NAE and NAE m/NAF)
Cytochemical stain.
Immunohistochemistry (IHC)
Naphthyl Butyrate Esterase
Cytochemical stain.
Immunohistochemistry (IHC)
Napsin A
Napsin A has a specific function in normal alveolar epithelium and is proposed to play a role in the proteolytic processing of surfactant precursors. Napsin A is reported to be predominantly expressed in lamellar bodies of type II pneumocytes, secondary lysosomes of alveolar macrophages, respiratory
Immunohistochemistry (IHC)
NeoARRAY™ SNP/Cytogenetic Profile
The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants
Cytogenetics
NeoARRAY™ SNP/Cytogenetic Profile
The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants
Molecular
NeoLAB™ AML Profile - Liquid Biopsy
This test is performed by sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2,
Molecular
NeoLAB™ BTK Inhibitor Acquired Resistance Panel - Liquid Biopsy
The NeoLAB™ BTK Inhibitor Acquired Resistance Panel is a blood test performed by modified properietary bi-directional sequencing of the BTK and PLC-gamma-2 genes using cell-free circulating tumor DNA (ctDNA). This method allows detection of mutations with sensitivity of 10(-4). Analysis includes the
Molecular
NeoLAB™ EGFR T790M - Liquid Biopsy
The NeoLAB EGFR T790M - Liquid Biopsy test is a sequencing based assay that can detect the EGFR T790M mutation in plasma with high sensitivity (0.1%) using cell-free circulating tumor DNA (cfDNA).
Molecular
NeoLAB™ FLT3 Mutation Analysis - Liquid Biopsy
Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing is performed on cell-free plasma DNA/RNA to increase
Molecular
NeoLAB™ IDH1 Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH1 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
Molecular
NeoLAB™ IDH2 Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH2 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
Molecular
NeoLAB™ inv(16), CBFB-MYH11 Translocation - Liquid Biopsy
Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript using cell-free plasma DNA/RNA. This assay identifies type A fusions, which account for >90%
Molecular
NeoLAB™ KIT (c-KIT) Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
Molecular
NeoLAB™ KRAS Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ KRAS Mutation Analysis- Liquid Biopsy will only
Molecular
NeoLAB™ MDS/CMML Profile - Liquid Biopsy
This test is performed by the sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, RUNX1, SETBP1,
Molecular
NeoLAB™ Myeloid Disorders Profile - Liquid Biopsy
This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1,
Molecular
NeoLAB™ NPM1 Mutation Analysis - Liquid Biopsy
PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
Molecular
NeoLAB™ NRAS Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ NRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological
Molecular
NeoLAB™ PML-RARA Translocation, t(15;17) - Liquid Biopsy
Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript using cell-free plasma DNA/RNA. Both long and short isoforms of the fusion transcript are detected.
Molecular
NeoLAB™ Prostate - Liquid Biopsy
NeoLAB Prostate is a qRT-PCR test designed to look at expression levels of the genes AR, B2M, ERG, GAPDH, HSPD1, IMPDH2, PCA3, PDLIM5, PSA, PTEN, TMPRSS2, and UAP1 in urine and plasma samples. The expression levels of these genes will be used in 2 different algorithms to determine a patients cancer
Molecular